If approved by the Drugs Controller General of India (DCGI), it will be the second vaccine after ZyCoV-D to get EUA for use among those below 18 years. The National Technical Advisory Group on Immunisation (NTAGI) is looking at how ZyCov-D should be positioned for most optimum use.

According to Paul, Covaxin is a part of the adult vaccination programme and how to provision the vaccine, if at all for children, has to be also examined in the totality of the requirements of the vaccination programme. “A pragmatic decision (on vaccination of children and adolescents) can be taken (only) by balancing the supply and the potential eligibility,” he said, adding, “The preparation for incorporation of Zydus Cadila’s vaccine into the vaccination programme is proceeding well, training is already being held. NTAGI advice for the best use of the vaccine is explored. So soon, this will be rolled out”.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!